• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by ACELYRIN INC.

    8/12/24 9:40:06 AM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLRN alert in real time by email
    SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.2 ACELYRIN INC COMMON STOCK Cusip #00445A100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #00445A100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 3,882,214 Item 6: 0 Item 7: 3,884,690 Item 8: 0 Item 9: 3,884,690 Item 11: 3.922% Item 12: HC Cusip #00445A100 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 3,884,690 Item 8: 0 Item 9: 3,884,690 Item 11: 3.922% Item 12: IN Item 1(a). Name of Issuer: ACELYRIN INC Item 1(b). Address of Issuer's Principal Executive Offices: 4149 LIBERTY CANYON RD AGOURA HILLS, CA 91301 US Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 00445A100 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 3,884,690 (b) Percent of Class: 3.922% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 3,884,690 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ACELYRIN INC. No one other person's interest in the COMMON STOCK of ACELYRIN INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. August 9, 2024 Date /s/ Richard Bourgelas Signature Richard Bourgelas Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on August 8, 2023, accession number: 0000315066-23-002397. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on August 9, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of ACELYRIN INC at July 31, 2024. FMR LLC By /s/ Richard Bourgelas Richard Bourgelas Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Richard Bourgelas Richard Bourgelas Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of Abigail P. Johnson* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on August 8, 2023, accession number: 0000315066-23-002397.
    Get the next $SLRN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLRN

    DatePrice TargetRatingAnalyst
    8/14/2024$18.00 → $6.00Buy → Neutral
    H.C. Wainwright
    7/8/2024$13.00Equal Weight → Overweight
    Wells Fargo
    12/13/2023$11.00Equal Weight
    Wells Fargo
    12/8/2023$8.00Neutral
    Citigroup
    9/13/2023$19.00Overweight → Equal-Weight
    Morgan Stanley
    9/5/2023$44.00Buy
    H.C. Wainwright
    5/30/2023Overweight
    Morgan Stanley
    5/30/2023$31.00Buy
    Jefferies
    More analyst ratings

    $SLRN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alumis Stockholders Approve Merger with ACELYRIN

      SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with ACELYRIN, INC. (NASDAQ:SLRN) at its Special Meeting of Stockholders. Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, "We thank our stockholders for their support for the merger and with this milestone now complete, we are moving expeditious

      5/13/25 1:00:00 PM ET
      $ALMS
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

      LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that at the Company's special meeting of stockholders held earlier today, its stockholders voted to approve the adoption of the Company's merger agreement with Alumis Inc. (NASDAQ:ALMS). As previously announced, under the terms of the amended merger agreement, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned at the closing of the transaction. "We appreciate our stockholders' support for our merger

      5/13/25 1:00:00 PM ET
      $ALMS
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote "FOR" the Proposed Transaction with Alumis

      ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today LOS ANGELES, May 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that leading independent proxy advisory firm Institutional Shareholder Services ("ISS") has recommended that ACELYRIN stockholders vote "FOR" the proposed merger ("Proposed Transaction") of the Company with Alumis Inc. (NASDAQ:ALMS). The Company's special meeting of stockholders to vote on the Proposed Transaction is scheduled for May 13, 2025. ACELYRIN urges its stockholders to vote FOR the Pr

      5/6/25 4:30:00 PM ET
      $ALMS
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRN
    Leadership Updates

    Live Leadership Updates

    See more
    • Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

      Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027 Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T. WAYNE, Pa. and ROCKVILLE, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced it has acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio, Inc. Concurrent with the acquisition, Ava

      3/27/24 4:01:00 PM ET
      $AVTX
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications

      Highly accomplished leader bringing more than 25 years of investor relations, communications, and operational & strategic finance experience at public healthcare companies LOS ANGELES, Feb. 15, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications. Reporting to Founder and CEO Shao-Lee Lin, MD, PhD, Ms. Lee will be responsible for leading investor relations and corporate communications and will join the company's Senior Leadership Team.

      2/15/24 4:05:00 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors

      LOS ANGELES, Dec. 20, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Lynn Tetrault to its board of directors. "I am pleased to welcome Lynn to our board of directors as we close our first year as a publicly traded company. Lynn is a highly accomplished biopharma executive and her extensive expertise spanning global human capital strategy, talent management, business operations, and corporate affairs adds a valuable dimension to support our evolving company," said Shao-Lee Lin, MD, PhD, Founder and CEO of ACELYRIN

      12/20/23 4:30:00 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ACELYRIN INC.

      SC 13G/A - ACELYRIN, Inc. (0001962918) (Subject)

      11/14/24 1:28:35 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ACELYRIN INC.

      SC 13G/A - ACELYRIN, Inc. (0001962918) (Subject)

      11/12/24 12:13:00 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ACELYRIN INC.

      SC 13G - ACELYRIN, Inc. (0001962918) (Subject)

      11/4/24 10:56:23 AM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRN
    Financials

    Live finance-specific insights

    See more
    • ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

      LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners' continued rapid accumulation of 8.8% of ACELYRIN'S outstanding common stock, its Board of Directors has approved the adoption of a limited-duration stockholder rights plan ("Rights Plan"). The ACELYRIN Board and management team continue to engage with stockholders and are focused on maximizing stockholder value. Pursuant to the Rights Plan, the Company is issuing one right for each share of common stock as of the close

      3/13/25 7:00:00 AM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

      Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN's lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple clinical readouts for highly differentiated late-stage portfolio Alumis and ACELYRIN stockholders to own ~55% and ~45%, respectively, of combined company on a fully diluted basis Combined company wi

      2/6/25 4:15:00 PM ET
      $ALMS
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease

      Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile Conducted positive end of Phase 2 FDA meeting; Phase 3 program expected to be initiated in Q1 2025 Topline Phase 3 data expected in second half of 2026; cash runway expected through mid-2027 Conference call to review unmet need in TED, new Phase 2 data and Phase 3 program design to be held today, January 6, 2025, at 4:30 PM ET LOS ANGELES, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery

      1/6/25 4:00:00 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ayurmaya Capital Management Company, Lp returned 9,334,735 shares to the company (SEC Form 4)

      4 - ACELYRIN, Inc. (0001962918) (Issuer)

      5/23/25 4:23:20 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Kim Mina was granted 89,526 shares and returned 770,833 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - ACELYRIN, Inc. (0001962918) (Issuer)

      5/23/25 4:11:54 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Cozadd Bruce C

      4 - ACELYRIN, Inc. (0001962918) (Issuer)

      5/23/25 4:11:07 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ACELYRIN downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded ACELYRIN from Buy to Neutral and set a new price target of $6.00 from $18.00 previously

      8/14/24 7:48:43 AM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ACELYRIN upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded ACELYRIN from Equal Weight to Overweight and set a new price target of $13.00

      7/8/24 8:17:02 AM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on ACELYRIN with a new price target

      Wells Fargo initiated coverage of ACELYRIN with a rating of Equal Weight and set a new price target of $11.00

      12/13/23 8:08:18 AM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRN
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by ACELYRIN INC.

      SCHEDULE 13D/A - ACELYRIN, Inc. (0001962918) (Subject)

      5/23/25 4:15:26 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by ACELYRIN INC.

      SCHEDULE 13D/A - ACELYRIN, Inc. (0001962918) (Subject)

      5/23/25 4:01:03 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by ACELYRIN INC.

      EFFECT - ACELYRIN, Inc. (0001962918) (Filer)

      5/23/25 12:15:04 AM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care